Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On

The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate.

Related Keywords

Madrid , Spain , Switzerland , Barcelona , Comunidad Autonoma De Cataluna , Italy , Boston , Massachusetts , United States , Poland , Lugano , Ticino , Svizzera Italiana , Tony Sk Mok , Zofia Piotrowska , Enriqueta Felip , Silke Gillessen , Federico Cappuzzo , Rafal Dziadziuszko , University Of Gdansk , Department Of Oncology , Department Of Medical Oncology , European Society For Medical Oncology , Hebron University Hospital , Hospital Cancer Center , Department Of Clinical Oncology , Chinese University Of Hong Kong , European Society , Medical Oncology , Medscape Medical , Lung Cancer Unit , Medical University , Clinical Oncology , Chinese University , Massachusetts General Hospital Cancer Center , Non Small Cell Lung Cancer , Nsclc , Lung Cancer , Ung Carcinoma , Ancer Lung , Neoadjuvant , Surgery , Adjuvant Therapy , Biologic Therapy , Cancer , Alignant Neoplasia , Arcinoma , Chemotherapy , Immunotherapy , Lung , Adjuvant Chemotherapy , Hospitals , Oncological Medicine , Tumor ,